美通社

2024-08-27 09:00

ArkBio Presented at the 8th Annual IPF Summit and Announced Completion of Patient Enrollment for Phase 2 Clinical Trial of AK3280, a Next-Generation Drug for IPF Treatment

BEIJING, Aug. 27, 2024 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio"), a privately held, clinical-stage biopharmaceutical company today announced that Dr. Jim Wu, Chief Executive Officer of ArkBio, gave an oral presentation entitled"Development of Next Generation Broadly Active IPF Drug AK3280"at the 8th Annual IPF Summit held in Boston on August 22, 2024. AK3280 is a next-generation broad-spectrum anti-fibrotic drug for the treatment of idiopathic pulmonary fibrosis (IPF) and is undergoing a randomized, double-blind, multicenter phase 2 PoC clinical study. The clinical trial led by Professor Huaping Dai of the China-Japan Friendship Hospital, Beijing, is being conducted across 31 hospitals in China to evaluate the safety, tolerability, and efficacy of AK3280 in IPF patients.

Dr. Wu stated:"Although there are already two IPF drugs on the market, both suffer from poor tolerability and lower efficacy that do not improve patient's symptoms. Successful completion of patient enrollment for Phase 2 study is an important milestone for AK3280 as a next generation broadly active IPF drug. We extend our sincere gratitude to all the patients and investigators who participated in the trial for their efforts and contribution. The safety and efficacy results from this study will provide key scientific evidence for the continuous clinical development of the drug. We will work closely with investigators to advance clinical development of AK3280 and address the unmet medical need in treatment of IPF. ArkBio commits to the pursuit of innovative drugs for the treatment of respiratory and pulmonary diseases."

About the 8th Annual IPF Summit

The IPF Summit is the largest IPF drug development forum for the pulmonary fibrosis research community. Its annual conference brings together pharmaceutical and biotech companies, clinicians, and academic researchers from around the globe with the goal to harness emerging biological understanding, apply novel and evolving models, and assess patient populations to propel innovative and efficacious pulmonary fibrosis therapeutics through phase 2 and beyond. For more information about the Annual IPF Summit conference, please visit ipf-summit.com. 

About Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive form of fibrosing interstitial pneumonia of unknown cause. IPF predominantly affects the elderly, with a median onset age of 65 years. The primary symptoms include progressively worsening shortness of breath, accompanied by restrictive ventilatory impairment and gas exchange abnormalities, leading to hypoxemia and even respiratory failure. The disease is confined to the lungs with pathological and/or radiological features consistent with usual interstitial pneumonia (UIP).

IPF has an insidious onset, followed by continuous, unpredictable, and irreversible progression. Its prognosis is worse than that of most lung cancers. The five-year survival rate is only 20% with a median survival time of just 2-3 years from diagnosis, which is why it is often considered a cancer-like disease. Smoking, respiratory viral infections, and environmental factors are potential risk factors for IPF.

About AK3280

AK3280 is a next-generation broad-spectrum anti-fibrotic molecule optimized from the marketed drug pirfenidone. It has the ability to modulate multiple pathways and biomarkers closely associated with the fibrotic process, including the expression of fibrosis-related genes and proteins induced by transforming growth factor-beta (TGF-β) and lysophosphatidic acid (LPA). AK3280 works by reducing cell proliferation and inhibiting the synthesis and accumulation of extracellular matrix. Compared to pirfenidone, AK3280 offers advantages in safety and tolerability, with potentially much better clinical efficacy. It is currently undergoing a phase 2 proof-of-concept clinical trial in patients with IPF in China.

About ArkBio

ArkBio is a global biotech company focusing on discovery and development of innovative drugs for unmet medical needs, especially in the areas of pediatric and respiratory/lung diseases. Since its inception in 2014, the company has established core technology platforms and built an innovative and highly differentiated R&D pipeline through in-house R&D efforts and external collaborations. One of the core drug products, ziresovir, is the first direct-acting RSV antiviral drug that successfully completed phase III clinical trial with positive results. Moreover, ziresovir is the first non-oncology drug that has received a breakthrough designation from NMPA. Another near-commercial drug asset is an attention deficit hyperactivity disorder (ADHD) drug AZSTARYS® that has been approved by FDA. ArkBio owns the right for its development and commercialization in Greater China. The R&D pipeline program also includes a battery of clinical and pre-clinical stage drug candidates with first- or best-in-class potential for global clinical development. 

ArkBio has established strategic partnerships with several multinational pharmaceutical companies and academic institutes, including Roche, Genentech, the Scripps Research Institute, the Institute of Microbiology of Chinese Academy of Sciences, domestic and global biotechnology companies, as well as venture investment institutions. 

For more information about the company, please visit our website www.arkbiosciences.com 

Investor Inquiries IR@arkbiosciences.com 

source: Shanghai Ark Biopharmaceutical Co., Ltd.

《說說心理話》青少年自殺率上升,如何分辨求助訊號?社工分享陪伴的重要性► 即睇

人氣文章
最近7天
1
高息定存 | 6個月港元定存3.8厘新高,188日快閃優惠3.68厘
2
高息定存 | 富邦推快閃定存優惠3個月3.9厘,華僑188日3.68厘
3
專訪|林本利系列專訪逢周五登場,股市篇:勿驚美股調整,港股那些可以放心買那些勿沾手(有片)
4
高息定存 | 工銀亞洲推3個月5厘息搶新客,招商永隆推快閃優惠
5
高息定存 | 信銀國際上調1個月定存年息至高達3.88厘
6
回顧展望-新股復燃 | 政策市激發IPO 惟六成新股破發損行情
7
神州經脈 | 特別國債或發3萬億,滬指逼近三千四,日外相訪華
8
回顧展望-國際形勢 | 全球動盪戰火連天,特朗普時代重臨
9
高息定存 | 聖誕前夕銀行加存息吸資金,大眾3個月加至3.6厘
10
【FOCUS】「晶片戰」揮新大棒,技術制華恐適得其反
11
【FOCUS】零售寒冬襲京滬港,逆市奇葩值借鏡
12
今日焦點股 | 據報螞蟻集團重組架構,劉政或出任首席財務官
13
神州經脈 | 工業利潤降幅收窄,低空經濟發展司成立,滬指全周升
14
港股 | 蕭猷華:恒指料退守至18600點,宜逢低吸納
15
神州經脈 | 換手機可獲政府補貼,政策利率將降,滬指周挫逾5%
16
內銀股 | 人行再提擇機減息降準,內銀獲中金唱好,應該點部署?
17
神州經脈 | PMI遜預期,滬指全年止跌回升,人幣年度貶幅擴
18
回顧展望-國際金融 | 金融市場現重要轉折,戰亂刺激避險
19
回顧展望-息息相關 | 銀行股明年看好滙控,重組有利減低支出
20
新股掛牌 | 布魯可首日掛牌升41%,每手賺7395元
21
高息定存 | 一周高息合集,銀行年尾搶資金,大眾3個月3.6厘
22
回顧展望-人幣走貶 | 關稅殺到,先貶為敬,人幣明年勢見7.5
23
大國博弈 | 【FOCUS】騰訊商湯寧德重挫,CMC清單劍指軍民融合
24
高息定存 | 一周高息合集,恒生1個月定存4厘,工銀亞洲3個月最高5厘
25
回顧展望-A股自強 | 憧憬國策利好,機構對明年股市走勢樂觀
26
加州山火 | 【FOCUS】洛杉磯烈火焚城,天災背後藏人禍
27
港股 | 蕭猷華:恒指維持19700點至21000點上落
28
藍圖2.0 | 旅遊發展藍圖2.0提四大策略,推特色項目智慧旅遊並開拓客源
29
高息定存 | 渣打特選客6個月3.48厘,建行亞洲推1個月6.18厘高息吸客
30
港股 | 蕭猷華:恒指春節前可挑戰21500點
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【etnet30周年連環賞】睇住賞Moon-River RELOVE 蛋白酵素去漬抑菌手洗精 (價值HK$188)

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

大國博弈

貨幣攻略

說說心理話

聖誕新年特輯

Watch Trends 2024

北上食買玩

Art Month 2024

秋天養生食療

山今養生智慧

輕鬆護老